BOSTON, LAUSANNE, Switzerland and TAIPEI CITY, Taiwan, March 9, 2022 /PRNewswire/ — SOPHiA GENETICS (NASDAQ:SOPH) today announced that SOFIVA GENOMICS, which is one of the largest genetic testing companies in Taiwan aiming to provide genetic testing to clinicians, is the first institution in Asia Pacific to adopt SOPHiA GENETICS’ technology to support HRD testing. SOFIVA GENOMICS has been deeply involved in the field of clinical medicine and cancer monitoring for many years and found great success while implementing the solution for advanced HRD (Homologous Recombination Deficiency) detection using deep learning with the SOPHiA DDM Platform.
SOPHiA GENETICS Announces SOFIVA GENOMICS To Adopt SOPHiA’s Technology To Support HRD Testing
BOSTON, LAUSANNE, Switzerland and TAIPEI CITY, Taiwan, March 9, 2022 /PRNewswire/ — SOPHiA GENETICS (NASDAQ:SOPH) today announced that SOFIVA GENOMICS, which is one of the largest genetic testing companies in
